Skip to content
DataLookout
Start free
Menu

NCT07407348

A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body

StatusActive, Not Recruiting
PhasePhase 1
Primary completion (estimated)

At risk: Primary completion moved at least 2 months later.

See at-risk trials from Boehringer Ingelheim

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 6 versions: 5 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria expanded, about 20 words
    • Primary and study completion dates pushed to Apr 9, 2027
  2. Enrollment closed, study ongoing
    • Site details revised
    v5
  3. Start date: Feb 26, 2026 to Mar 11, 2026v3
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Mar 2, 2026 to Feb 26, 2026
    • Site details revised
    v2
  5. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Area under the concentration-time curve of survodutide in plasma at steady state over a uniform dosing interval tau (AUC tau,ss)
Timeframe: Up to 239 days.
Maximum measured concentration of survodutide in plasma at steady state over a uniform dosing interval tau (Cmax,ss)
Timeframe: Up to 239 days.

Arms and interventions

Formulation A, then Formulation B6Experimental
Formulation B6, then Formulation AExperimental

Combination products: Formulation A, Formulation B6

Sites

1 site in 1 country

  • Quotient SciencesNottingham, United Kingdom